Cardiac sympathetic activity and lethal arrhythmic events: insight into bell-shaped relationship between

Kenichi Nakajima1, Tomoaki Nakata2, Takahiro Doi3

  • 1Department of Nuclear Medicine/Functional imaging and Artificial Intelligence, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan. nakajima@med.kanazawa-u.ac.jp.

EJNMMI Research
|July 20, 2024
PubMed

Insights

The relationship between cardiac 123I-meta-iodobenzylguanidine (mIBG) uptake and lethal arrhythmic events (ArE) shows a bell-shaped curve in certain chronic heart failure patients. This finding helps identify those at higher risk for ArE.

Area of Science:

  • Cardiology
  • Nuclear Medicine
  • Medical Imaging

Background:

  • 123I-meta-iodobenzylguanidine (mIBG) is used in chronic heart failure (CHF) patients.
  • The link between mIBG cardiac activity and lethal arrhythmic events (ArE) requires further clarification.

Purpose of the Study:

  • To investigate the relationship between cardiac 123I-mIBG activity and ArE in Japanese and European cohorts.
  • To identify patient subgroups at higher risk for ArE based on mIBG imaging parameters.

Main Methods:

  • Analysis of heart-to-mediastinum (H/M) count ratios and washout rates (WRs) from planar 123I-mIBG imaging in 827 CHF patients.
  • Definition of ArE including sudden cardiac death, arrhythmic death, and potentially lethal events.
  • Machine learning models incorporating 13 clinical variables to simulate ArE rates.

Main Results:

  • A bell-shaped relationship between H/M ratios and ArE incidence was observed in the European cohort and in patients with NYHA classes II/III combined.
  • This bell-shaped pattern was particularly evident in patients with high mIBG WR (>15%) and ischemic etiology.
  • Machine learning predictions confirmed a bell-shaped ArE risk curve in NYHA class II/III patients.

Conclusions:

  • The relationship between cardiac 123I-mIBG activity and ArE is patient-dependent.
  • A bell-shaped relationship in specific patient groups (NYHA II/III, high WR, ischemic etiology) aids in identifying high-risk individuals for ArE.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
732
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
563
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
909
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
962
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
ECG Interpretation of Arrhythmias I: Sinus Arrhythmias01:16

ECG Interpretation of Arrhythmias I: Sinus Arrhythmias

Arrhythmias are disturbances in the heart's rhythm that lead to abnormal heartbeats. These irregularities can originate from different parts of the heart and are classified based on their origin and nature.
Types of Arrhythmias
Sinus Node Arrhythmias
Sinus Bradycardia: Originating from the sinoatrial (SA) node, sinus bradycardia involves slower impulses, resulting in a heart rate of less than 60 beats per minute (bpm). Causes include sleep, vagal stimulation, beta-blockers, hypothyroidism,...
208